This study indicated that salidroside defends against NAFLD by alleviating hepatic lipid metabolism, reducing the release of inflammatory factors, and inhibiting NLRP3 inflammasome activation in vivo and in vitro, which were related to the regulation of the TXNIP/NLRP3 pathways (Zheng et al., 2018). This evidence concerns the gene TXNIP and metabolic dysfunction-associated steatotic liver disease.